Terapi kansè nan òvèj ki reziste platinum resevwa terapi dekouvèt

Avril 13, 2022
by Linda Hohnholz
Li min li
A HOLD FreeRelease 2 | eTurboNews | eTN
Ekri pa Linda Hohnholz

InxMed Co., Ltd. announced that IN0018 had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin….

eTurboNews atik yo se pou abonnés sèlman. Abònman se GRATIS.
Abonnés konekte isit la Klike la a pou w abònman GRATIS

KISA POU RETIRE NAN ATIK SA A:

  • This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin….
  • .
  • announced that IN0018 had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration.
Ekri an lèt detacheLinkedInTelegramWhatsAppVKMessengerSMSRedditFlipboardPinteresttumblrXingTanponNouvèl piratèliyMelanjePòchYummlyKopi

<

Ou tou ka renmen

Sou otè a

Linda Hohnholz

Editè an chèf pou eTurboNews ki baze nan HQ eTN.

Wè tout posts
Pataje pou...
TanponKopiFlipboardNouvèl piratèliyLinkedInMessengerMelanjePinterestPòchEkri an lèt detacheRedditSMSTelegramtumblrVKWhatsAppXing